Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.59 |
| ▸ | LIPE | Q05469 | 2/20 | 0.58 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.47 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.47 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30116505 | 1.00 | ENPP2 (0.59) | ENPP2LIPEORAI1ORAI2ORAI3 | |
| SCHEMBL2546391 | 0.91 | ENPP2 (0.57) | ENPP2LIPEORAI1ORAI2ORAI3 | |
| SCHEMBL18171929 | 0.86 | LIPE (0.63) | ENPP2LIPEORAI1ORAI2ORAI3 | |
| SCHEMBL18171926 | 0.86 | LIPE (0.63) | ENPP2LIPEORAI1ORAI2ORAI3 | |
| SCHEMBL2556728 | 0.83 | LIPE (0.61) | ENPP2LIPELMNAMAPTALDH1A1 | |
| SCHEMBL29952366 | 0.82 | LIPE (0.59) | ENPP2LIPEORAI1ORAI2ORAI3 | |
| SCHEMBL3654163 | 0.82 | ENPP2 (0.61) | ENPP2LIPEORAI1ORAI2ORAI3 | |
| SCHEMBL29619443 | 0.82 | ENPP2 (0.61) | ENPP2LIPEORAI1ORAI2ORAI3 | |
| SCHEMBL1684575 | 0.82 | LIPE (0.59) | ENPP2LIPEORAI1ORAI2ORAI3 | |
| SCHEMBL2974587 | 0.81 | MAPT (0.56) | LMNAJAK2GAAMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264159-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| WO-2025034849-A1 | FUSED PYRIDAZINES FOR THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| US-12187684-B2 | Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2025-01-07 | — | — | US | disclosed |
| EP-4476204-A1 | COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS | Theras, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| US-20240262828-A1 | Functionalized Heterocycles as Antiviral Agents | ENANTA PHARM INC (US) | 2024-08-08 | — | — | US | disclosed |
| US-11891393-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-06 | — | — | US | disclosed |
| WO-2023154282-A1 | COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20230212131-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230212131-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230212131-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2023-07-06 | — | — | US | disclosed |
| WO-2009023964-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2009-02-26 | — | — | WO | disclosed |
| WO-2008124849-A2 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20080221119-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-7361763-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361764-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| WO-2007106236-A2 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| EP-1781654-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20070043068-A1 | to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine | SGX PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20060030583-A1 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2006-02-09 | — | — | US | disclosed |
| WO-2006015123-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240262828-A1 | Functionalized Heterocycles as Antiviral Agents | HCCS, HAVCR2, HDGF | ENPP2 3296/4885LIPE 4333/4885ORAI1 3981/4885 |
| US-20230212131-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | COL1A1, COL2A1, COL14A1 | ENPP2 2419/4885LIPE 4541/4885ORAI1 4056/4885 |
| US-20080221119-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | MAP3K20, MAP4K2, MAP3K19 | ENPP2 1932/4885LIPE 4373/4885ORAI1 3338/4885 |
| US-11891393-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | ENPP2 3296/4885LIPE 4333/4885ORAI1 3981/4885 |
| US-20060030583-A1 | Pyrrolo-pyridine kinase modulators | MAP3K20, MAP4K2, MAP3K19 | ENPP2 1932/4885LIPE 4373/4885ORAI1 3338/4885 |
| US-12187684-B2 | Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical use thereof | RORC, RORB, RORA | ENPP2 3943/4885LIPE 3337/4885ORAI1 4386/4885 |
| US-20070043068-A1 | to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine | MAP3K20, MAP4K2, MAP3K6 | ENPP2 688/4885LIPE 3639/4885ORAI1 3698/4885 |
| US-12264159-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | ENPP2 3296/4885LIPE 4333/4885ORAI1 3981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.